139 related articles for article (PubMed ID: 33389657)
21. A Rare Case of Essential Thrombocythemia with Coexisting
Jang MA; Seo MY; Choi KJ; Hong DS
J Korean Med Sci; 2020 Jun; 35(23):e168. PubMed ID: 32537949
[TBL] [Abstract][Full Text] [Related]
22. Different involvement of the megakaryocytic lineage by the JAK2 V617F mutation in Polycythemia vera, essential thrombocythemia and chronic idiopathic myelofibrosis.
Hussein K; Brakensiek K; Buesche G; Buhr T; Wiese B; Kreipe H; Bock O
Ann Hematol; 2007 Apr; 86(4):245-53. PubMed ID: 17262192
[TBL] [Abstract][Full Text] [Related]
23. Driver mutations (JAK2V617F, MPLW515L/K or CALR), pentraxin-3 and C-reactive protein in essential thrombocythemia and polycythemia vera.
Lussana F; Carobbio A; Salmoiraghi S; Guglielmelli P; Vannucchi AM; Bottazzi B; Leone R; Mantovani A; Barbui T; Rambaldi A
J Hematol Oncol; 2017 Feb; 10(1):54. PubMed ID: 28228104
[TBL] [Abstract][Full Text] [Related]
24. [Correlation of JAK2V617F mutation burden with clinical features in patients with polycythemia vera and essential thrombocythemia].
Liu HX; Tong CR; Cai P; Teng W; Wang H; Zhang Y; Zhu P
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2009 Jun; 17(3):742-5. PubMed ID: 19549399
[TBL] [Abstract][Full Text] [Related]
25. [Latent essential thrombocythemia becoming perceptible after splenectomy].
Hatsuse M; Taminishi Y; Maegawa-Matsui S; Fuchida SI; Inaba T; Murakami S; Shimazaki C
Rinsho Ketsueki; 2019; 60(5):387-391. PubMed ID: 31168000
[TBL] [Abstract][Full Text] [Related]
26. Clinical correlates of JAK2V617F presence or allele burden in myeloproliferative neoplasms: a critical reappraisal.
Vannucchi AM; Antonioli E; Guglielmelli P; Pardanani A; Tefferi A
Leukemia; 2008 Jul; 22(7):1299-307. PubMed ID: 18496562
[TBL] [Abstract][Full Text] [Related]
27. JAK2V617F mutation and allele burden are associated with distinct clinical and morphological subtypes in patients with essential thrombocythaemia.
Pich A; Riera L; Beggiato E; Nicolino B; Godio L; Campisi P; Sismondi F; di Celle PF
J Clin Pathol; 2012 Oct; 65(10):953-5. PubMed ID: 22718845
[No Abstract] [Full Text] [Related]
28. Expression analysis of microRNA-125 in patients with polycythemia vera and essential thrombocythemia and correlation with JAK2 allele burden and laboratory findings.
Ferdowsi S; Atarodi K; Amirizadeh N; Toogeh G; Azarkeivan A; Shirkoohi R; Faranoush M; Vaezi M; Alimoghaddam K; Ghavamzadeh A; Naghadeh HT; Ghaffari SH
Int J Lab Hematol; 2015 Oct; 37(5):661-7. PubMed ID: 26011312
[TBL] [Abstract][Full Text] [Related]
29. Bilateral Adrenal Infarction That Developed in Latent Essential Thrombocythemia.
Hada Y; Yamada A; Kobayashi T; Sugiyama T; Ishii K; Takase K; Takakubo N; Nagaoka K; Karasawa S; Kameda W; Ishizawa K; Susa S
Intern Med; 2024 Feb; 63(3):419-423. PubMed ID: 37344430
[TBL] [Abstract][Full Text] [Related]
30. Essential differences in clinical and bone marrow features in BCR/ABL-positive thrombocythemia compared to thrombocythemia in the BCR/ABL-negative myeloproliferative neoplasms essential thrombocythemia and polycythemia vera.
Michiels JJ; Pich A; De Raeve H; Gadisseur A
Acta Haematol; 2015; 133(1):52-5. PubMed ID: 25116159
[No Abstract] [Full Text] [Related]
31. Distinguishing essential thrombocythemia
Silver RT; Krichevsky S
Haematologica; 2019 Nov; 104(11):2200-2205. PubMed ID: 30948488
[TBL] [Abstract][Full Text] [Related]
32. The JAK2V617F allele burden and STAT3- and STAT5 phosphorylation in myeloproliferative neoplasms: early prefibrotic myelofibrosis compared with essential thrombocythemia, polycythemia vera and myelofibrosis.
Risum M; Madelung A; Bondo H; Bzorek M; Kristensen MH; Stamp IM; Hasselbalch HC
APMIS; 2011 Aug; 119(8):498-504. PubMed ID: 21749449
[TBL] [Abstract][Full Text] [Related]
33. [Correlations of jak2v617f mutation with clinical and laboratory findings in primary thrombocythemia patients].
Xia J; Xu W; Zhang SJ; Sun XM; Duan LM; Li WD; Qiou HX; Li JY
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2008 Apr; 16(2):416-20. PubMed ID: 18426677
[TBL] [Abstract][Full Text] [Related]
34. JAK2V617F mutation is common in old patients with polycythemia vera and essential thrombocythemia.
Randi ML; Ruzzon E; Tezza F; Scapin M; Duner E; Scandellari R; Fabris F
Aging Clin Exp Res; 2011 Feb; 23(1):17-21. PubMed ID: 21499015
[TBL] [Abstract][Full Text] [Related]
35. JAK2V617F mutation and hydroxyurea treatment as determinants of immature platelet parameters in essential thrombocythemia and polycythemia vera patients.
Panova-Noeva M; Marchetti M; Buoro S; Russo L; Leuzzi A; Finazzi G; Rambaldi A; Ottomano C; Ten Cate H; Falanga A
Blood; 2011 Sep; 118(9):2599-601. PubMed ID: 21750318
[TBL] [Abstract][Full Text] [Related]
36. JAK2V617F, CALR, and MPL Mutations and Bone Marrow Histology in Patients with Essential Thrombocythaemia.
Pich A; Riera L; Francia di Celle P; Beggiato E; Benevolo G; Godio L
Acta Haematol; 2018; 140(4):234-239. PubMed ID: 30404086
[TBL] [Abstract][Full Text] [Related]
37. [Significance of the JAK2V617F mutation in patients with chronic myeloproliferative neoplasia].
Iványi JL; Marton E; Plander M
Orv Hetil; 2011 Nov; 152(45):1795-803. PubMed ID: 22011365
[TBL] [Abstract][Full Text] [Related]
38. Non-driver mutations in patients with JAK2V617F-mutated polycythemia vera or essential thrombocythemia with long-term molecular follow-up.
Senín A; Fernández-Rodríguez C; Bellosillo B; Camacho L; Longarón R; Angona A; Besses C; Álvarez-Larrán A
Ann Hematol; 2018 Mar; 97(3):443-451. PubMed ID: 29181548
[TBL] [Abstract][Full Text] [Related]
39. The impact of JAK2V617F mutation on different types of thrombosis risk in patients with essential thrombocythemia: a meta-analysis.
Qin Y; Wang X; Zhao C; Wang C; Yang Y
Int J Hematol; 2015 Aug; 102(2):170-80. PubMed ID: 25997869
[TBL] [Abstract][Full Text] [Related]
40. JAK2V617F mutation and circulating extracellular vesicles in essential thrombocythemia.
Aswad MH; Kissova J; Ovesna P; Říhová L; Penka M
Clin Hemorheol Microcirc; 2023; 84(4):359-368. PubMed ID: 37334581
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
